These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 8675099)

  • 1. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
    Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
    Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.
    Arnold R; Neuhaus C; Benning R; Schwerk WB; Trautmann ME; Joseph K; Bruns C
    World J Surg; 1993; 17(4):511-9. PubMed ID: 8395752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group.
    Arnold R; Benning R; Neuhaus C; Rolwage M; Trautmann ME
    Digestion; 1993; 54 Suppl 1():72-5. PubMed ID: 8359572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
    Tomassetti P; Migliori M; Corinaldesi R; Gullo L
    Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting formulations of somatostatin analogues.
    Anthony LB
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).
    Wynick D; Anderson JV; Williams SJ; Bloom SR
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):385-8. PubMed ID: 2557179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
    Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
    Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.
    Burgess JR; Greenaway TM; Parameswaran V; Shepherd JJ
    Cancer; 1999 Nov; 86(10):2154-9. PubMed ID: 10570446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
    Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
    Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours.
    Welin SV; Janson ET; Sundin A; Stridsberg M; Lavenius E; Granberg D; Skogseid B; Oberg KE; Eriksson BK
    Eur J Endocrinol; 2004 Jul; 151(1):107-12. PubMed ID: 15248829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors.
    Trendle MC; Moertel CG; Kvols LK
    Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
    Arnold R; Frank M; Kajdan U
    Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
    Kwekkeboom DJ; Teunissen JJ; Bakker WH; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; Esser JP; Kam BL; Krenning EP
    J Clin Oncol; 2005 Apr; 23(12):2754-62. PubMed ID: 15837990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
    Klijn JG; Hoff AM; Planting AS; Verweij J; Kok T; Lamberts SW; Portengen H; Foekens JA
    Br J Cancer; 1990 Oct; 62(4):627-30. PubMed ID: 1977468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.
    Degen L; Beglinger C
    Digestion; 1999; 60 Suppl 2():9-14. PubMed ID: 10207226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.